Ganstigmine (CHF2819) is an acetylcholinesterase inhibitor that increases acetylcholine in rat hippocampus and ameliorates scopolamine-induced amnesia. In this article, we examined whether and how ganstigmine might prevent or rescue the neurodegenerative phenotype in AD11 antinerve growth factor (anti-NGF) mice, a transgenic model for Alzheimer's disease. The effects of ganstigmine were compared with those obtained after administration of donepezil. Results demonstrate that intraperitoneal and oral administration of ganstigmine and donepezil can reverse the cholinergic and behavioral deficit in AD11 mice but not the amyloid and phosphotau accumulation, uncovering different mechanisms leading to neurodegeneration in AD11 mice.
Giacobini E: Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry.2003; 18(Suppl 1): S1-S5.
3.
Tariot PN, Federoff HJ: Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord.2003; 17(Suppl 4): S105-S113.
4.
Pietra C, Villetti G, Bolzoni PT, et al.: Cholinesterase inhibitory activity of new geneserine derivatives. Alzheimer Dis Assoc Disord. 1999: 689-696.
5.
Trabace L, Cassano T, Steardo L, et al.: Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther.2000; 294(1): 187-194.
6.
Windisch M, Hutter-Paier B, Jerkovic L, et al.: The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. Neurosci Lett.2003; 341(3): 181-184.
7.
Capsoni S, Giannotta S, Cattaneo A: Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Mol Cell Neurosci.2002; 21(1): 15-28.
8.
Capsoni S, Giannotta S, Cattaneo A: Early events of alzheimer like neurodegeneration in anti-nerve growth factor transgenic mice. Brain Aging.2002; 2: 24-43.
9.
Capsoni S, Ugolini G, Comparini A, et al.: Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci.2000; 97(12): 6826-6831.
10.
Ruberti F, Capsoni S, Comparini A, et al.: Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci.2000; 20(7): 2589-2601.
11.
Pesavento E, Capsoni S, Domenici L, et al.: Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of antinerve-growth-factor mice. Eur J Neurosci.2002; 15(6): 1030-1036.
12.
Franklin KBJ, Paxinos GT: The Mouse Brain in Stereotaxic Coordinates.San Diego: Academic Press, 1997.
13.
Russo C, Salis S, Dolcini V, et al.: Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Neurobiol Dis. 2001; 8(1): 173-180.
14.
Capsoni S, Giannotta S, Cattaneo A: Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci. 2002; 99(19): 12432-12437.
15.
Ridley RM, Baker, HF: A critical evaluation of monkey models of amnesia and dementia. Brain Res Rev.1991; 16: 15-37.
16.
Beatty W, Winn P, Adams R, et al.: Preserved cognitive skills in dementia of the Alzheimer type. Arch Neurol.1994; 51: 1040-1046.
17.
Ennaceur A, Delacour J: A new one-trial test for neurobiological studies of memory in rats: 1: Behavioral data. J Behav Brain Res. 1988; 31: 47-59.
